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Abstract
Preventing pathological ocular angiogenesis is key to treating retinopathy of prematurity, diabetic retinopathy and age-
related macular degeneration. At present there is no small molecule drug on the market to target this process and hence
there is a pressing need for developing novel small molecules that can replace or complement the present surgical and
biologic therapies for these neovascular eye diseases. Previously, an antiangiogenic homoisoflavanone was isolated from
the bulb of a medicinal orchid, Cremastra appendiculata. In this study, we present the synthesis of a novel
homoisoflavanone isomer of this compound. Our compound, SH-11052, has antiproliferative activity against human
umbilical vein endothelial cells, and also against more ocular disease-relevant human retinal microvascular endothelial cells
(HRECs). Tube formation and cell cycle progression of HRECs were inhibited by SH-11052, but the compound did not induce
apoptosis at effective concentrations. SH-11052 also decreased TNF-a induced p38 MAPK phosphorylation in these cells.
Intriguingly, SH-11052 blocked TNF-a induced IkB-a degradation, and therefore decreased NF-kB nuclear translocation. It
decreased the expression of NF-kB target genes and the pro-angiogenic or pro-inflammatory markers VCAM-1, CCL2, IL8,
and PTGS2. In addition SH-11052 inhibited VEGF induced activation of Akt but not VEGF receptor autophosphorylation.
Based on these results we propose that SH-11052 inhibits inflammation induced angiogenesis by blocking both TNF-a and
VEGF mediated pathways, two major pathways involved in pathological angiogenesis. Synthesis of this novel
homoisoflavanone opens the door to structure-activity relationship studies of this class of compound and further
evaluation of its mechanism and potential to complement existing antiangiogenic drugs.
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Introduction
Angiogenesis is a tightly controlled, complex physiological
process involving the formation of new blood vessels from pre-
existing ones. Under normal conditions, angiogenesis does not
occur in the body, except during development and wound repair
processes. However, during numerous pathological conditions
angiogenesis occurs, notably in ocular diseases such as retinopathy
of prematurity (ROP), diabetic retinopathy (DR), and ‘‘wet’’ age-
related macular degeneration (AMD). Collectively, these diseases
are a major cause of blindness through the lifespan [1].
Clinical symptoms of DR are seen in 75% of diabetic patients,
with 10% of them eventually developing visual impairment [1].
DR is currently the leading cause of blindness among working age
adults and accounts for 8% of the legal blindness in the United
States [1]. Similarly, AMD is responsible for causing blindness in
elderly people worldwide. Wet AMD affects approximately 2
million people in the United States and is estimated to engender a
productivity burden of nearly $5.4 billion [2]. In the United States,
70% of the infants with very low birth weight develop ROP after
exposure to postnatal hyperoxia. Around 1,300 infants per year in
the United States develop complete vision loss due to this disease,
and 500 more are severely impaired [3]. Overall, between 6% and
18% of childhood blindness is attributable to ROP [4]. Moreover,
as more and more children survive premature birth in middle
income countries due to improvements in neonatal intensive care,
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ROP is becoming more prevalent worldwide [4]. Thus, these three
diseases, along with other neovascular diseases of the eye,
represent a significant public health problem.
After pathological angiogenesis, newly formed blood vessels are
fragile, porous and not fully differentiated. The formation of such
new blood vessels in the eye leads to various complications such as
hemorrhage, retinal detachment, fibrotic scarring and rapid
photoreceptor degradation. If these conditions are left untreated,
irreversible vision loss can occur. Cryotherapy, laser therapy and
surgical interventions are major treatment options for neovascular
eye diseases, yet they are also associated with vision-damaging side
effects [5]. Recently, drug therapy using biologics such as
bevacizumab, pegaptanib and aflibercept has been successful in
treating these diseases [5,6]. An antibody, aptamer, and fusion
protein respectively, these drugs all act by inhibiting vascular
endothelial growth factor (VEGF) signaling, a key pro-angiogenic
signaling pathway [1]. However these medications face an
unfavorable cost to benefit ratio [7,8] and have the potential for
significant acute systemic side effects such as non-ocular hemor-
rhage and myocardial infarction [5]. There is also a significant
population that is refractory to these drugs; up to 45% in one series
of AMD patients [9]. In addition, during pathological conditions,
levels of inflammatory cytokines such as TNF-a and IL-1 are
elevated and these cytokines in turn promote angiogenesis along
with VEGF [10,11]. Hence targeting not only VEGF signaling but
multiple proangiogenic signals is required to improve the efficacy
of treatment for diseases arising from pathological angiogenesis. At
present there is currently no small molecule drug on the market to
specifically prevent angiogenesis in the eye, hence there is a
pressing need to develop specific novel small molecule drugs to
treat these blinding eye diseases.
Several small molecules, including natural products, have been
identified that inhibit pathological angiogenesis such as artemisi-
nin, curcumin, fumagillin, LLL12, panduratin, decursin, with-
aferin, and sunitinib [12–18]. A recent addition to this group is a
homoisoflavanone, 5,7-dihydroxy-3-(3-hydroxy-4-methoxyben-
zyl)-6-methoxychroman-4-one that was isolated from the plant
Cremastra appendiculata (D. Don) (Compound 1; Fig. 1A). The bulb
of the orchid C. appendiculata is a traditional medicine in East Asia,
used internally to treat several cancers, and externally for skin
lesions [19–21]. This compound has also been isolated from
members of the Hyacinthaceae, a rich source of homoisoflava-
nones, which are a small class of naturally occurring heterocyclic
compounds that are structurally similar to isoflavonoids [22].
Compound 1 was shown to possess anti-angiogenic activity both
in vitro and in vivo [21,23,24]. Shim et al. identified compound 1 as
a potent inhibitor of the proliferation of human umbilical vein
endothelial cells (HUVECs) [21]. Later it was shown that
compound 1 inhibited both vascular tube formation and migration
of HUVECs induced by basic fibroblast growth factor (bFGF) in
vitro. In the chick chorioallantoic membrane model, compound 1
was as effective as retinoic acid in blocking new vessel growth
induced by bFGF [21]. The anti-angiogenic property of the
compound as isolated from the plant extract was further confirmed
in vivo in the laser-induced choroidal neovascularization and
oxygen induced retinopathy mouse models, used for treatment
evaluations in neovascular AMD and in ROP, respectively
[23,24]. Importantly, injection of compound 1 into the vitreous
of normal adult mice showed no short-term cytotoxic or
inflammatory effects on the retina, nor did it induce apoptosis of
retinal cells [23]. These results suggest that proliferative ocular
vascular diseases such as ROP, DR, and AMD may be targeted
using compound 1 or its derivatives.
In order to further explore the potential of homoisoflavanones
as treatments for neovascular eye diseases, we synthesized a novel
isomer of compound 1, 5,6-dihydroxy-3-(3-hydroxy-4-methoxy-
benzyl)-7-methoxychroman-4-one, known as SH-11052 (com-
pound 2, Fig. 1A). In the present study we report this synthesis
and show the anti-angiogenic properties of compound 2 in human
retinal microvascular endothelial cells (HRECs). We also demon-
strate that compound 2 blocks TNF-a induced NF-kB signaling
and the VEGF-induced PI3K/Akt pathway, two major proangio-
genic signaling pathways activated during inflammation induced
angiogenesis. These results suggest that the compound exerts its
anti-angiogenic properties by blocking inflammation-induced
angiogenic pathways.
Materials and Methods
Materials Used
HRECs and Attachment Factor were purchased from Cell
Systems (Kirkland, WA, USA). Clonetics HUVECs were pur-
chased from Lonza (Walkersville, MD, USA). All cells were used
between passages 5 and 7. Endothelial Growth Medium (EGM-2)
was prepared by mixing the contents of an EGM-2 ‘‘Bullet Kit’’
(Cat no. CC-4176) with Endothelial Basal Medium (EBM)
(Lonza). The EGM-2 ‘‘Bullet Kit’’ contains hydrocortisone,
human fibroblast growth factor (hFGF), VEGF, R3-insulin like
growth factor (R3-IGF-1), ascorbic acid, human epidermal growth
Figure 1. Homoisoflavanone SH-11052 inhibits proliferation of endothelial cells. The effects of SH-11052 (2), an isomer of the natural-
source homoisoflavanone 1 (A) on the proliferation of HUVECs (B) and HRECs (C) were tested by alamarBlue fluorescence in the concentration range
of 0.5 nM to 500 mM and shown as mean 6 SEM relative to DMSO control. Dose response curves and indicated GI50 values were generated using
GraphPad Prism software.
doi:10.1371/journal.pone.0095694.g001
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factor (hEGF), gentamycin and heparin along with 2% fetal bovine
serum (FBS). Compound BAY 11-7082, caffeic acid phenethyl
ester (CAPE), TNF-a, and a-tubulin antibody were from Sigma
(St. Louis, MO, USA), and human VEGF-165 was from
BioLegend (San Diego, CA, USA). The antibodies for p38
MAPK, NF-kB p65 and VCAM-1 were obtained from Santa
Cruz (Dallas, TX, USA) while the cleaved caspase-3, phospho p38
MAPK, Akt, phospho-Akt, VEGFR2, phospho-VEGFR2, and
IkB-a antibodies were from Cell Signaling (Danvers, MA, USA).
Secondary antibodies were from Thermo Fisher Scientific
(Pittsburgh, PA, USA). The TaqMan probes and 59-ethynyl-29-
deoxyuridine (EdU) incorporation assay kit were procured from
Life Technologies (Carlsbad, CA, USA). AbD Serotec (Kidlington,
UK) was the source of the alamarBlue, while BD Biosciences (San
Jose, CA, USA) supplied the Matrigel. The Bradford reagent for
protein estimation was prepared by dissolving 0.3 g of Coomassie
G-250 (Pierce) in 500 mL of 3% perchloric acid.
Synthesis of SH-11052
Full details of synthetic methodology and chemical character-
ization of all intermediates and the final compound 2 is provided
in Methods S1 in File S1. Assignment was confirmed by 2D-NMR
(Figure S1 in File S1).
Cell Proliferation Assay
In a 96-well clear bottom black plate, cells (2,500 cells per well)
were seeded in a total volume of 100 mL EGM-2. After 24 hours
of incubation of the plate at 37uC and 5% CO2, a DMSO solution
of compound 2, BAY 11-7082, or CAPE was added in the
concentration range of 0.5 nM to 500 mM (final DMSO
concentration = 1%). The plate was then further incubated for
48 hours before adding 11.1 mL of alamarBlue reagent to each
well. Four hours after the addition of alamarBlue, fluorescence
readings with excitation and emission wavelengths of 560 nm and
590 nm respectively were taken and the data were analyzed in
GraphPad Prism software (v. 6.0). Dose response curves were
generated and the GI50 values were calculated using the following
equation: Y=100/(1+10‘(X2Log(GI50))).
EdU Incorporation Assay
Cells (25,000 per coverslip) were seeded onto coverslips coated
with Attachment Factor placed in a 6-well plate and incubated
with the indicated concentrations of compound 2 in EGM-2 for
24 hours at 37uC and 5% CO2. The cells were then serum starved
for 8 hours and the medium was replaced with EGM-2 containing
10 mM EdU. The plate was further incubated for another 8 hours
before processing the cells for detection of labeled DNA (according
to the manufacturer’s instructions for the Click-iT EdU assay kit).
Images were taken using an EVOS fluorescence microscope
(AMG, Mill Creek, WA, USA) and the number of DAPI stained
and EdU stained cells were counted in six randomly chosen fields
using ImageJ software.
In Vitro Angiogenesis Assay
Matrigel assays were performed as previously described [25],
with slight modifications for the use of HRECs. Briefly, HRECs
were starved overnight at 0.5% FBS in EBM-2 and plated on a 96-
well plate at a density of 7,500 cells/well over 50 mL of Matrigel
high concentration basement membrane. Compound 2 was added
at the indicated concentrations in EBM-2+1% FBS. Cells were
observed every 2 hours by bright field microscopy at 406
magnification for tube formation. Closed units (polygons) were
manually counted at 8 hours post plating and numbers normalized
to the DMSO control. Assays were performed in triplicate.
Caspase-3 Immunofluorescence Assay
Cells (25,000 per coverslip) were seeded onto coverslips coated
with Attachment Factor and incubated at 37uC and 5% CO2 in
EGM-2 until ,80% confluence was achieved. The cells were then
incubated for 4 hours with the indicated concentrations of
compound 2. Staurosporine (SP; 1 mM) was used as a positive
control. After the incubation, the cells were fixed in 4%
paraformaldehyde for 20 min at room temperature followed by
three quick washes in Tris buffered saline pH 7.4 (TBS). The cells
were permeabilized by incubating with 0.5% Triton X-100 for
10 minutes and then blocked in 10% block solution (DAKO,
Glostrup, Denmark) in TBS plus 1% bovine serum albumin (BSA)
for 1 hour. The cells were then incubated with cleaved caspase-3
(D175) antibody (1:200 dilution) overnight at 4uC. Dylight 555
conjugated goat anti-rabbit secondary antibody (1:400) was used
to probe the cleaved caspase-3 antibody. The coverslips were
mounted using Vectashield mounting medium containing DAPI
(Vector Labs, Burlingame, CA, USA) for nuclear staining. The
cells were imaged using an LSM 700 confocal microscope (Zeiss,
Thornwood, NY, USA).
NF-kB Nuclear Translocation Assay
Cells (25,000 per coverslip) were seeded onto coverslips coated
with Attachment Factor and incubated at 37uC and 5% CO2 for
24 hours in EGM-2. The cells were starved in 0.1% serum-EBM-2
for 8 hours followed by 0.1% serum-EBM-2 medium for one hour
in the presence of different concentrations of compound 2. The
cells were induced with 10 ng/ml TNF-a for 20 minutes and fixed
with 4% paraformaldehyde solution for 20 min at room temper-
ature. Cells were quickly washed three times in TBS and
permeabilized by incubating with 0.5% Triton X-100 for
10 minutes. The cells were blocked in 10% block solution
(DAKO) in TBS plus 1% BSA followed by incubation with an
antibody against NF-kB p65 (1:50 dilution). Dylight 488-conju-
gated goat anti-mouse secondary antibody (1:200 dilution) was
used to probe the NF-kB p65 antibody. The coverslips were
mounted using Vectashield mounting medium containing DAPI
(Vector Labs) for nuclear staining. The cells were imaged using an
LSM 700 confocal microscope (Zeiss).
VCAM-1 Expression Study
Cells (25,000 per coverslip) were seeded onto coverslips coated
with Attachment Factor and incubated at 37uC and 5% CO2 for
24 hours in EGM-2. The cells were starved in 0.1% serum-EBM-2
for 8 hours followed by incubation in 0.1% serum-EBM-2
medium for an hour in the presence of different concentrations
of compound 2. The cells were challenged with 10 ng/ml of TNF-
a for 24 hours and fixed with 4% paraformaldehyde solution for
20 minutes at room temperature. The coverslips were quickly
washed three times in TBS and blocked using 10% block solution
(DAKO) prepared in 16 TBS-1% BSA buffer. The coverslips
were incubated with the antibody against VCAM-1 (1:100
dilution) for 16 hours at 4uC followed by three washes in TBS-
0.1% BSA buffer. Dylight 555-conjugated secondary antibody
(1:200) was used to probe for the VCAM-1 antibody. After three
washes in TBS-0.1% BSA, the coverslips were mounted using
Vectashield mounting medium containing DAPI nuclear stain.
The cells were imaged using an LSM 700 confocal microscope.
The image was analyzed for fluorescence signal intensity using
MetaMorph software (Molecular Devices, Sunnyvale, CA, USA).
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qRT-PCR
Cells (105 per well) were seeded in a 6-well plate and incubated
for 24 hours at 37uC and 5% CO2. The cells were then starved in
0.1% serum-EBM-2 for 12 hours followed by incubation for an
hour in the presence of different concentrations of compound 2.
The cells were then challenged for 24 hours with 10 ng/ml TNF-
a. Following incubation, cells were lysed and RNA was isolated
using Trizol reagent (Life Technologies). cDNA was prepared
from 80 ng total RNA using random primers and M-MuLV
Reverse Transcriptase (New England Biolabs, Ipswich, MA, USA).
RT-PCR reactions were set up using the TaqMan Fast Gene
Expression Assay Kit according to the manufacturer’s instructions.
FAM-labeled TaqMan probes for PTGS2 (Hs00153133_m1),
CCL2 (Hs00234140_m1), IL8 (Hs00174103_m1), and TBP
(Hs99999910_m1) genes were used to monitor the expression
levels of these genes. The qRT-PCR plate was read in a ViiATM 7
qPCR system (Life Technologies) and the data were analyzed
using the DDCt method. The expression levels of genes were
normalized to TBP gene expression and calibrated to the DMSO-
treated, unstimulated sample.
Immunoblot
HRECs were seeded at 105 cells/well in a 6-well plate and after
24 hours of incubation at 37uC, cells were serum starved in 0.1%
serum-EBM-2 for 8 hours. Cells were then treated with the
indicated concentrations of compound 2 for one hour before the
addition of 20 ng/ml of TNF-a or 100 ng/ml VEGF. After
20 minutes, cells were lysed in NP-40 Lysis buffer containing
25 mM HEPES pH 7.4, 1% NP-40, 150 mM NaCl, 10%
glycerol, 1 mM sodium orthovanadate, 10 mM sodium fluoride,
1 mM sodium pyrophosphate, 1 mM PMSF, 2.5 mg/ml aproti-
nin, 1 mM pepstatin, and 1 mM leupeptin. Equal amounts of
proteins (80 mg), as measured by a Bradford assay, were run on
10% SDS-PAGE, transferred to PVDF membrane, blocked with
5% BSA in TBS-0.05% Tween-20 and immunoblotted with the
indicated primary antibodies (1:1000 in 1% BSA in TBS-0.05%
Tween-20) overnight at 4uC. After three washes in TBS-0.05%
Tween-20, HRP-conjugated secondary antibodies (1:5000 in 5%
BSA in TBS-0.05% Tween-20) were applied for one hour at room
temperature. After three washes, the protein bands were detected
and densitized using ECL Prime western blot detection reagent
(GE Life Sciences, Piscataway, NJ, USA) and an XRS gel
documentation system running Quantity One software (Bio-Rad).
Target protein band intensity was normalized to housekeeping
gene a-tubulin. For phosphoprotein analysis, normalized signal of
each phosphoprotein was expressed relative to the normalized
total amount of that protein.
Statistical Analysis
EdU incorporation, tube formation, apoptosis, immunoblot,
and VCAM-1 staining assay data were analyzed by ANOVA with
Dunnett’s post hoc tests for comparisons between drug treatments
and control. All analyses were performed with GraphPad Prism (v.
6.0). A p-value,0.05 was considered statistically significant in all
tests.
Results
Synthesis of SH-11052
To begin to explore synthetic homoisoflavanones as antiangio-
genic compounds, we synthesized a regioisomer of compound 1,
the novel homoisoflavanone SH-11052 (2; Fig. 1A). Homoiso-
flavanones consist of a chromanone with a substituted benzyl
group at the C3 position in the C ring. Among them, compound 2
is a unique homoisoflavanone comprising dihydroxy at the C5 and
C6 positions and a methoxy at the C7 position, respectively, with a
39-hydroxy-49-methoxybenzyl group at the C3 position of
chromanone. This compound has not previously been reported,
although syntheses of similar compounds are known [26–30]. The
substantial challenge associated with the total synthesis of
compound 2 was to uncover three phenolic groups on the C5,
C6 (in the A ring) and C39 (in the B ring) positions. For synthesis of
homoisoflavanone 2 and analogs, we envisaged the chromanone
ring formation by the treatment of a dihydrochalcone with
formaldehyde and a regioselective demethylation among the
methoxy groups of the A and B rings.
Figure 2. Synthesis of novel homoisoflavanone SH-11052 (2). Reagents and conditions: a) acetic anhydride, BF3-OEt2; b) 5, KOH, MeOH, 0uC,
56%; c) Pd/C, HCO2Na, HCO2H, 60uC, 79%; d) formalin, NaOH, 60uC, 54% for 8, 10% for 9, and 15% for 10; e) K2CO3, EtOH, 49% from 8, 72% from 10; f)
TMSI, CHCl3, 49%.
doi:10.1371/journal.pone.0095694.g002
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As shown in Fig. 2, our approach toward the synthesis of
compound 2 commenced with an aldol condensation of the 69-
hydroxy-29,39,49-trimethoxy-acetophenone 4, which was prepared
from 39,49,59-trimethoxyphenol 3 [31] with 3-benzyloxy-4-meth-
oxybenzaldehyde 5 to afford the resulting chalcone 6 in moderate
yield. Catalytic hydrogenation of the chalcone 6 under HCO2Na
and Pd/C afforded the dihydrochalcone 7. With the dihydro-
chalcone 7 in hand, the chromanone ring was constructed by
hydroxymethylation and cyclization. To this end, the desired
chromanone 9 was obtained in good yield by aldol reaction with
formaldehyde under basic conditions, and subsequent treatment
with K2CO3 of the concomitant compounds 8 and 10. Finally,
two methyl groups were selectively removed by excess of TMSI
(6,8 equivalents) to give SH-11052 (2). Note that our synthetic
molecule 2 is a racemate; the configuration at C3 for compound 1
has not been reported. Further experiments are necessary to
determine the absolute configuration of the C3 position in
compound 1.
SH-11052 Inhibits Proliferation of HRECs
It has been reported that compound 1 isolated from C.
appendiculata showed antiproliferative effects with a 50% growth
inhibitory (GI50) concentration value in the low micromolar range
in a HUVEC proliferation assay [21,23]. In order to test if SH-
11052 (2) has similar effects, the proliferation of HUVECs induced
by complete medium was monitored in the presence of compound
2 in the concentration range of 0.5 nM to 500 mM. As shown in
Fig. 1B, compound 2 inhibited HUVEC proliferation in a dose
dependent manner with GI50 = 18 mM. Once the antiproliferative
activity of compound 2 against HUVECs was confirmed, the
proliferation of the more disease-relevant HRECs was tested in the
presence of compound 2 in the same concentration range. As
Figure 3. SH-11052 blocks DNA synthesis in endothelial cells. After treatment with the indicated concentrations of SH-11052 (2) and an EdU
pulse, the HUVECs (A, B) and HRECs (C, D) were stained with DAPI (for nucleus - blue) and incorporated EdU (in proliferating cells – red) using a Click-iT
kit (Life Technologies). The cells were counted from 6 different fields of a coverslip and the percentage of proliferating HUVECs (B) and HRECs (D) was
calculated from the ratio of EdU stained cells to DAPI stained cells in each section (dots in the graphs) using ImageJ analysis software. The lines
indicate the mean 6 SEM and *** indicates p,0.0001 (ANOVA with Dunnett’s post hoc test). Representative data from three independent
experiments.
doi:10.1371/journal.pone.0095694.g003
Synthesis & Mechanism of a Novel Homoisoflavanone
PLOS ONE | www.plosone.org 5 April 2014 | Volume 9 | Issue 4 | e95694
shown in Fig. 1C, HREC proliferation was significantly inhibited
by compound 2 with GI50 = 43 mM. In order to confirm the
inhibition of cell proliferation, we monitored incorporation of 5-
ethynyl-29-deoxyuridine (EdU) into endothelial cells in the
presence of compound 2 (Fig. 3). DNA synthesis in both HRECs
and HUVECs was significantly inhibited in a dose dependent
manner by this compound.
SH-11052 Inhibits In Vitro Angiogenesis without Inducing
Apoptosis
The effect of compound 2 on the angiogenic ability of HRECs
was evaluated using an in vitro Matrigel tube formation assay.
HRECs treated with compound 2 showed a significant reduction
in their tube formation ability as compared to DMSO treated
samples (Fig. 4A). In the presence of compound 2 at the GI50
value, there was a significant reduction in tube formation and the
network of tubes was disrupted (polygon spaces in Fig. 4A) and at
120 mM the tube formation ability was completely abolished
(Fig. 4B). However, even at 100 mM, compound 2 caused
negligible apoptosis of HRECs as determined by cleaved
caspase-3 staining (Fig. 4C and 4D).
SH-11052 Inhibits the TNF-a Mediated NF-kB Pathway
After establishing the anti-angiogenic activity of compound 2,
we examined the mechanistic details of its activity in HRECs. As
inflammation plays a crucial role in pathological angiogenesis [32–
35], we examined the effect of compound 2 on inflammatory
signaling in endothelial cells. HRECs were treated with different
concentrations of compound 2 and then induced with TNF-a, a
known pro-inflammatory cytokine and inducer of NF-kB. Since
NF-kB exerts its transcriptional activity in the nucleus, blockade of
stimulus-induced nuclear translocation of NF-kB is an indication
of NF-kB pathway inhibition [36]. The nuclear translocation of
NF-kB upon TNF-a stimulation was inhibited by compound 2 in
a dose dependent manner as monitored by immunofluorescence
(Fig. 5A). IkB-a is an inhibitory protein that binds to NF-kB and
prevents its nuclear translocation. Upon TNF-a stimulation, IkB-a
is phosphorylated and degraded, freeing NF-kB for nuclear
translocation [37]. In the presence of compound 2, the TNF-a-
mediated degradation of IkB-a was significantly decreased in a
dose dependent manner, further indicating that compound 2 is
inhibiting NF-kB signaling (Fig. 5B–C). In order to confirm
inhibition of the TNF-a pathway, we monitored the activating
phosphorylation of p38 mitogen activated protein kinase (MAPK),
an important downstream target of the TNF-a pathway involved
in cytokine induced cell proliferation [38]. Compound 2 inhibited
phosphorylation of p38 MAPK in a dose dependent manner
(Fig. 5D–E).
To confirm that NF-kB pathway inhibition can lead to
decreased proliferation of HRECs, we treated these cells with
NF-kB pathway specific inhibitors BAY 11-7082, which inhibits
TNF-a induced phosphorylation of IkB-a [39], and caffeic acid
phenethylester (CAPE), which can block NF-kB-mediated tran-
scription [40]. Both compounds inhibited proliferation of HRECs
in a dose dependent manner with GI50 values of 4 mM for BAY
11-7082 and 36 mM for CAPE.
Figure 4. SH-11052 inhibits in vitro angiogenesis without causing apoptosis. (A) Tube formation on Matrigel by HRECs in the presence of
the indicated concentrations of 2. (B) Polygons formed (open spaces) were counted. Mean6 SEM of n = 3 wells. *, p,0.05; ***, p,0.001 compared to
DMSO control (ANOVA with Dunnett’s post hoc test). (C) HRECs were treated with indicated concentrations of 2 or staurosporine (SP) and stained
with DAPI (for nucleus - blue) and activated caspase-3 antibody (red). (D). Percentage of HRECs undergoing apoptosis was calculated by counting
number of caspase (red) stained cells compared to total (blue) cells using ImageJ software. Mean 6 SEM of cells from 3 different sections;
representative data from two independent experiments. *** p,0.001 compared to DMSO control (ANOVA with Dunnett’s post hoc test).
doi:10.1371/journal.pone.0095694.g004
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SH-11052 Decreases Levels of NF-kB Targets
We confirmed NF-kB pathway inhibition by monitoring the
expression of NF-kB induced genes in the presence of compound 2
(Fig. 6). VCAM-1 is a cell adhesion molecule specifically expressed
on endothelial cells and its expression is induced by NF-kB upon
TNF-a signaling [41,42]. We monitored the expression of VCAM-
1 in HRECs using immunofluorescence with increasing concen-
trations of compound 2. There was a significant dose-dependent
decrease in VCAM-1 protein expression in the presence of
compound 2 (Fig. 6A & 6B). Similarly the mRNA expression of
the pro-inflammatory molecules IL8, PTGS2 (COX2) and CCL2
(MCP-1), inducible by NF-kB, were decreased in the presence of
compound 2, as monitored by qRT-PCR (Fig. 6C).
SH-11052 Inhibits VEGF-mediated Activation of PI3K/Akt
Signaling:
As VEGF signaling is a major contributor to angiogenesis, we
tested if compound 2 can inhibit VEGF signaling along with
inflammation induced TNF-a signaling. Upon VEGF stimulation,
VEGF receptor 2 (VEGFR2) autophosphorylates, leading to
activation of the PI3K/Akt pathway [43]. Compound 2 did not
inhibit phosphorylation of VEGFR2 but inhibited activation of the
downstream Akt in HRECs (Fig. 7). Since TNF-a signaling also
feeds through Akt to IKKa [44], these results suggest that
compound 2 might act at the level of PI3K or Akt to block both
VEGF and TNF-a signaling.
Figure 5. SH-11052 inhibits TNF-amediated NF-kB signaling. (A) After treating HRECs with the indicated concentrations of 2, p65 (green) was
detected by immunofluorescence and nuclei (blue) stained with DAPI. Representative data from three independent experiments. (B) The protein
levels of IkB-a were measured after TNF-a treatment in the presence of the indicated concentrations of compound 2 by immunoblot. (D) The
phosphorylation level of p38 MAPK in HRECs stimulated with TNF-a was monitored in the presence of the indicated concentrations SH-11052 by
immunoblot. (C & E) Densitometry was performed using Quantity One software and analyzed using GraphPad Prism. The lines indicate the mean 6
SEM of three biological replicates and * indicates p,0.05 compared to TNF-a treatment (ANOVA with Dunnett’s post hoc test.
doi:10.1371/journal.pone.0095694.g005
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Discussion
In pathological ocular neovascularization such as that observed
in ROP, DR and AMD, there is an increase in the levels of VEGF
[45,46]. Along with VEGF, inflammation plays a crucial role in
pathological angiogenesis, as we and others have shown
[11,35,45,47]. This suggests that pathologic vessel growth as
observed in ocular diseases is not only under control of VEGF
[48], but also intimately linked with inflammation leading to
endothelial activation [34,42]. Of the several cell signal transduc-
tion pathways studied, NF-kB pathways play an important role in
inducing the expression of pro-angiogenic genes such as VEGF,
VEGFR, IL8, VCAM1, CCL2, and PTGS2 after activation through
TNF-a signaling [33,45,49]. Based on the clinical evidence that
anti-VEGF antibody therapy led to arterial thromboembolic
complications and suggested a role for endothelial damage and
inflammation [50], a combination of anti-VEGF and anti-
inflammatory therapy might be more beneficial in treating
neovascular eye disease than monotherapy. In favor of this
hypothesis, in ROP experimental models, a combination of
inhibitors of different pathways was found to be highly significant
in blocking new vessel formation [51].
At present, the current antiangiogenic biologics only target
VEGF signaling at the level of the receptor. Therefore, the
development of drugs targeting inflammatory signals provides an
opportunity for new, combination anti-angiogenic therapies.
Developing small molecules to include in such cocktails is thus
of significant interest and development of drugs which can inhibit
multiple angiogenic pathways would greatly increase the efficacy
of therapies. Towards this goal we have pursued SH-11052 as a
small molecule inhibitor of retinal neovascularization, building on
previous reports of the efficacy of a related homoisoflavanone (1)
in animal models of ROP and choroidal neovascularization
[23,24].
In the present study we have used a novel method based on a
chalcone intermediate and a regioselective demethylation (Fig. 2)
to synthesize the novel homoisoflavanone 2. This methodology
adds to the diversity of homoisoflavanones that are synthetically
tractable and will readily allow synthesis of novel analogs in future.
We have confirmed that our synthetic SH-11052 has similar
effects on HUVECs to the natural-source compound 1 (Fig. 1B).
GI50 of the natural product 1 was reported as 0.5 mg/mL, or
approximately 1.5 mM [21].
Endothelial cells from different tissues have different gene
expression patterns suggesting different physiological effects [52].
HUVECs are macrovascular endothelial cells which do not have
specific relevance to the microvascular endothelial cells that are
present in retinal capillaries of the eye. Therefore, we tested SH-
11052 in HRECs, where it proved similarly potent as an anti-
proliferative molecule (Fig. 1C), albeit at higher GI50, consistent
with the hypothesis that microvascular endothelial cells differ from
macrovascular endothelial cells. SH-11052 blocks proliferative
progression through DNA synthesis in both HUVECs and
HRECs (Fig. 3). This is consistent with the documented G2/M
phase cell cycle arrest induced by 1 in HUVECs [24]. We have
also demonstrated the in vitro anti-angiogenic activity of 2 in a
Matrigel HREC tube formation assay, similar to the effects of 1 in
HUVECs [24].
Figure 6. SH-11052 decreases the expression of NF-kB target genes. (A) Endothelial activation marker VCAM-1 (red) was detected by
immunofluorescence in HRECs exposed to TNF-a6 2. (B) MetaMorph fluorescence intensity analysis of VCAM-1 staining in the presence of TNF-a and
the indicated concentrations of 2, mean6SEM of n= 5 fields; *, p,0.05 **, p,0.01 compared to DMSO control (ANOVA with Dunnett’s post hoc test);
representative data from two independent experiments. (C) qRT-PCR using TaqMan probes showed that mRNA levels of NF-kB target genes IL8
(interleukin-8) (left panel), CCL2 (MCP-1) and PTGS2 (COX2) (right panel), all induced by TNF-a, were decreased in the presence of 2 in a dose
dependent manner. Note different y-axis scales. Mean 6 SEM of n = 3 replicates shown; representative data from two independent experiments.
doi:10.1371/journal.pone.0095694.g006
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The novel anti-angiogenic mechanism of homoisoflavanones
remains largely unexplored. In HUVECs, compound 1 induced
expression of p21WAF1 (CDKN1A), an inhibitor of the cyclin-
dependent kinase Cdc2 (CDK1), which in turn is downregulated by
compound 1 [24]. Homoisoflavanone 1 also blocked prostaglan-
din synthesis from arachidonic acid in a microsome assay, without
marked effects on function of cyclooxygenases 1 and 2 as purified
enzymes [53]. In keratinocytes, compound 1 inhibited the nuclear
translocation of NF-kB under ultraviolet light-induced inflamma-
tory conditions, suggesting a role of the compound in modulating
inflammatory signals in these cells [54]. In this context, compound
1 also decreased phosphorylation of the MAPKs Jun N-terminal
kinase (JNK), p38 MAPK, and ERK.
We examined if the activity of SH-11052 in HRECs may
likewise be mediated through modulation of inflammatory signals.
As NF-kB is the principal mediator of inflammation induced
signals [55], we monitored NF-kB activation upon TNF-a
stimulation in the absence or presence of compound 2 in HRECs.
NF-kB is a transcription factor sequestered in the cytoplasm by
association with IkB-a protein. Upon TNF-a stimulation, IkB-a is
phosphorylated and degraded by the proteasome, releasing free
NF-kB. The free NF-kB is then translocated into the nucleus and
aids in the transcription of its target genes. Hence monitoring the
protein levels of IkB-a and nuclear translocation of NF-kB upon
TNF-a treatment are measures of the activation of the NF-kB
pathway by inflammatory signals [55]. Indeed, we show that IkB-
a degradation and nuclear translocation of NF-kB in HRECs are
inhibited by compound 2 (Fig. 5). Furthermore, compound 2 also
inhibited the expression of NF-kB inducible pro-angiogenic and
pro-inflammatory genes (Fig. 6), suggesting a role for compound 2
in the inhibition of inflammation-induced pro-angiogenic signaling
in HRECs.
SH-11052’s suppressive effects on expression of IL8 and PTGS2
in HRECs are consistent with the observed effects of the natural
product 1 in keratinocytes. To our knowledge, we show for the
first time an effect of a homoisoflavanone on the endothelial
activation marker and NF-kB target, VCAM-1, and on the
inflammatory marker CCL2. Thus, the data presented here are
consistent with a function for compound 2 as an inhibitor of NF-
kB signaling in HRECs. NF-kB has previously been implicated in
pathological ocular angiogenesis [56,57] and we further confirmed
that two known NF-kB pathway inhibitors, BAY 11-7082 [39] and
CAPE [40], had antiproliferative effects on HRECs.
This assertion of an NF-kB-dependent role for compound 2 can
integrate others’ findings regarding the activities of the related
compound 1 in other cell types as well. bFGF can act by signaling
through phospholipase Cc1 [58,59], which activates protein kinase
C (PKC) a via diacylglycerol. In turn, PKCa binds and activates
IKKa, which phosphorylates and inactivates I-kB [60]. Thus,
blockade of this pathway would inhibit cellular responses to bFGF,
as seen with compound 1 in HUVECs [21]. NF-kB is a major
transcription factor for inflammatory cytokines, and also for
transcription of PTGS2 [61], consistent with the negative
transcriptional effects of compound 1 on these genes and
consequent inhibition of prostaglandin production in keratino-
cytes. Mitochondrial superoxide dismutase (SOD2) transcription is
also activated by NF-kB [62], potentially explaining increased
reactive oxygen species generation after NF-kB inhibition
Figure 7. SH-11052 inhibits VEGF mediated Akt signaling. Phosphorylation of VEGFR2 (A) and Akt (C) was monitored in HRECs upon VEGF
stimulation in the presence of varying concentrations of 2. (B & D) Densitometry was performed using Quantity One software and analyzed using
GraphPad Prism. The lines indicate the mean 6 SEM of three biological replicates, * indicates p,0.05 and ** indicates p,0.01 compared to VEGF
treatment alone (ANOVA with Dunnett’s post hoc test).
doi:10.1371/journal.pone.0095694.g007
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mediated by compound 1 [54]. Moreover, blockade of the NF-kB
pathway can deactivate MAPKs, as seen with compound 1 [54] in
keratinocytes and compound 2 in HRECs (Fig. 5). This may occur
via sequestration of the MAPK kinase kinase TPL2 (tumor
progression locus 2) by (inactive) p105NFKB1 [63]. Finally, NF-kB
inhibition can lead to upregulated p53-mediated transcription
[64], which could increase levels of p21WAF1 and decrease Cdc2
expression in response to treatment with compound 1 as
previously seen in HUVECs [24]. A role for both compounds 1
and 2 in the NF-kB pathway is also consistent with possible
mechanisms for related isoflavones [65], and NF-kB pathway
inhibition has previously been shown to block pathogenic ocular
neovascularization [56].
Compound 2 may be acting at the level of PI3K or Akt, since
compound 2 can inhibit VEGF-induced Akt phosphorylation, but
not VEGFR2 phosphorylation (Fig. 7), and since PI3K/Akt serves
as a point of integration of both VEGF and TNF signaling [44]. As
a post-receptor VEGFR signaling inhibitor and TNF-a pathway
inhibitor, compound 2 may serve as a lead molecule for targeting
multiple proangiogenic pathways to improve the efficacy of
treatment. Development of such molecules which target both
VEGF and other inflammation induced proangiogenic signaling
pathways might help in replacing or reducing the dose of anti-
VEGF biologics. Future studies identifying the direct molecular
interacting partners of homoisoflavanones in HRECs will be
crucial for elucidating their precise anti-angiogenic mechanism, as
well as optimizing the structures of these molecules prior to future
therapeutic use, via a target-based drug discovery approach.
In summary, we have synthesized a novel homoisoflavanone 2
and demonstrated its anti-angiogenic activity in retinal endothelial
cells, and provided partial characterization of its molecular
mechanism. Given SH-11052’s anti-angiogenic properties, it will
be important to fully elucidate the molecular mechanism of action
of this compound. Our synthetic method also enables structure-
activity profiling to obtain more potent anti-angiogenic molecules
that can be tested in animal models of ocular neovascularization,
both alone and in combination therapies.
Supporting Information
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